These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
181 related items for PubMed ID: 25265876
1. Combinations of various CpG motifs cloned into plasmid backbone modulate and enhance protective immunity of viral replicon DNA anthrax vaccines. Yu YZ, Ma Y, Xu WH, Wang S, Sun ZW. Med Microbiol Immunol; 2015 Aug; 204(4):481-91. PubMed ID: 25265876 [Abstract] [Full Text] [Related]
2. Potentiation of anthrax vaccines using protective antigen-expressing viral replicon vectors. Wang HC, An HJ, Yu YZ, Xu Q. Immunol Lett; 2015 Feb; 163(2):206-13. PubMed ID: 25102364 [Abstract] [Full Text] [Related]
3. Three types of human CpG motifs differentially modulate and augment immunogenicity of nonviral and viral replicon DNA vaccines as built-in adjuvants. Yu YZ, Li N, Ma Y, Wang S, Yu WY, Sun ZW. Eur J Immunol; 2013 Jan; 43(1):228-39. PubMed ID: 23037552 [Abstract] [Full Text] [Related]
4. Enhanced potency of replicon vaccine using one vector to simultaneously co-express antigen and interleukin-4 molecular adjuvant. Ma Y, An HJ, Wei XQ, Xu Q, Yu YZ, Sun ZW. Hum Vaccin Immunother; 2013 Feb; 9(2):242-9. PubMed ID: 23291932 [Abstract] [Full Text] [Related]
5. Pentavalent replicon vaccines against botulinum neurotoxins and tetanus toxin using DNA-based Semliki Forest virus replicon vectors. Yu YZ, Liu S, Ma Y, Gong ZW, Wang S, Sun ZW. Hum Vaccin Immunother; 2014 Feb; 10(7):1874-9. PubMed ID: 25424795 [Abstract] [Full Text] [Related]
6. Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant. Park YS, Lee JH, Hung CF, Wu TC, Kim TW. Infect Immun; 2008 May; 76(5):1952-9. PubMed ID: 18285494 [Abstract] [Full Text] [Related]
7. Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers. Rynkiewicz D, Rathkopf M, Sim I, Waytes AT, Hopkins RJ, Giri L, DeMuria D, Ransom J, Quinn J, Nabors GS, Nielsen CJ. Vaccine; 2011 Aug 26; 29(37):6313-20. PubMed ID: 21624418 [Abstract] [Full Text] [Related]
8. Immunostimulatory CpG oligonucleotides: Effect on gene expression and utility as vaccine adjuvants. Klinman DM, Klaschik S, Tomaru K, Shirota H, Tross D, Ikeuchi H. Vaccine; 2010 Feb 23; 28(8):1919-23. PubMed ID: 20188247 [Abstract] [Full Text] [Related]
9. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. Boyaka PN, Tafaro A, Fischer R, Leppla SH, Fujihashi K, McGhee JR. J Immunol; 2003 Jun 01; 170(11):5636-43. PubMed ID: 12759444 [Abstract] [Full Text] [Related]
16. Immunostimulatory capacity of DNA vaccine vectors in porcine PBMC: a specific role for CpG-motifs? Verfaillie T, Cox E, Goddeeris BM. Vet Immunol Immunopathol; 2005 Jan 10; 103(1-2):141-51. PubMed ID: 15626469 [Abstract] [Full Text] [Related]